Renal Cell Carcinoma

During a Targeted Oncology™ Case-Based Roundtable™ event, Randy F. Sweis, MD, discussed possible therapy options for a patient with metastatic renal cell carcinoma whose disease progressed on frontline therapy.

During a live, virtual event, Thomas Hutson, DO, PharmD, discussed the case of a 54-year-old man with a history of metastatic renal cell carcinoma.

Yousef Zakharia, MD, discusses the COSMIC-313 study and its implications to date.

Looking at the results of the BIONIKK trial, Yann-Alexandre Vano, MD, discusses the importance of having biomarkers drive treatment decisions in patients with metastatic renal cell carcinoma.

Chung-Han Lee, MD, PhD, reviews clinical trial data and how they apply to the evolving treatment landscape in non-clear cell renal cell carcinoma.

In an interview with Targeted Oncology™, Yousef Zakharia, MD discussed evidence supporting both doublet and triplet therapy for the treatment of previously untreated, advanced/metastatic renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumanta K. Pal, MD, discussed the updated results of frontline trials of patients with metastatic renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Deepak Kilari, MD, discussed with participants their impressions of tyrosine kinase inhibitor plus immune checkpoint inhibitor trials for patients with metastatic renal cell carcinoma.

In the second article of this series, Chandler H. Park, MD, a genitourinary oncologist at Norton Cancer Institute, reviews recently updated data on advanced renal cell carcinoma treatments.

Combination therapy with checkpoint blockade, also termed immuno oncology agents, and multikinase tyrosine kinase inhibitors are rapidly becoming the first-line therapy of choice in patients with metastatic clear cell renal cell carcinoma.

A panel of expert genitourinary oncologists give an overview of renal cell carcinoma and present the case of a 61-year-old man with metastatic clear cell RCC.

Pedro C. Barata, MD, MSc, explains how the favorable efficacy and tolerability of lenvatinib and pembrolizumab observed in the CLEAR trial helps provide a standard of care in this patient population.

Sumanta “Monty” K. Pal, MD, FASCO, discuss exciting data in the renal cell carcinoma space.

In separate live, virtual events, Ulka N. Vaishampayan, MBBS, and David A. Braun, MD, PhD, discussed options for a patient with favorable-risk clear cell renal cell carcinoma.

With updated data for the usefulness of tivozanib, patients with recurrent clear cell renal carcinoma have an effective option for treatment in a treatment landscape previously without many treatment options.

Chandler H. Park, MD, discusses the treatment landscape for advanced renal cell carcinoma and factors that influence treatment decisions.

During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew T. Campbell, MD, MS, discussed data supporting frontline combination therapies for patients with favorable- and intermediate-risk clear cell renal cell carcinoma.

Findings from the phase 3 CONTACT-03 fail to add evidence supporting immune checkpoint inhibitor and tyrosine kinase inhibitor combination therapy for advanced renal cell carcinoma.

Yann-Alexandre Vano, MD, explains the methods and design of the phase 2 BIONIKK trial for patients with renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Martin H. Voss, MD, discussed with participants their goals and approaches when considering third-line therapy for patients with advanced clear cell renal cell carcinoma.

In the first article of this series, Moshe Ornstein, MD, a genitourinary medical oncologist at the Cleveland Clinic, gives an overview of renal cell carcinoma and discusses the treatment landscape.

Patients with advanced renal cell carcinoma showed positive improvements in survival and toxicity outcomes when given nivolumab monotherapy, salvage nivolumab, and ipilimumab.

Dr Moshe Ornstein provides an overview of renal cell carcinoma (RCC) and treatment considerations for patient who have progressed with advanced RCC.

Nivolumab and sunitinib combined in the first-line treatment continues to maintain benefit for patients with advanced or metastatic renal cell carcinoma.

The phase 3 ZIRCON trial of 89Zr-DFO-girentuximab in clear cell renal cell carcinoma met its end point by exceeding high sensitivity and specificity thresholds.